Evidence-based·Updated November 20, 2026·How we grade evidence

Allopurinol

MedicationXanthine oxidase inhibitor for gout (prescription)

Allopurinol is the most widely used uric acid-lowering medicine. Trials show it brings more people to target uric acid than placebo, and it is approved for gout, cancer-treatment uric acid and certain kidney stones. Randomized trials found it did not prevent heart events in older adults with heart disease or slow kidney decline in chronic kidney disease, uses it is not approved for. Its key risks are rare but serious skin and hypersensitivity reactions. The critical interaction is with azathioprine.

Taking Allopurinol with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with gout, people receiving cancer treatment that raises uric acid, and adults with recurrent calcium oxalate stones and high urine uric acid, whose prescriber recommends it

Common dosing range

Set by your prescriber: for gout, usually 100 mg a day to start, raised by 100 mg each week until blood uric acid is 6 mg/dL or less, up to 800 mg a day; lower in kidney disease

When to expect effects

Uric acid falls within weeks, but the label says gout control can take several months, and flares may increase at first

Watch out for

The label says to stop it and seek care at the first sign of a rash: rare severe skin reactions (SJS, TEN, DRESS) can be fatal, and risk is higher with the HLA-B*58:01 gene. No boxed warning. Critical interaction with azathioprine and mercaptopurine

What is it

Allopurinol is a prescription medicine that lowers uric acid. It is taken by mouth as generic allopurinol tablets (100 mg and 300 mg) or Zyloprim tablets; Aloprim is an injected form given in hospital to people with cancer who cannot take tablets. The tablet label approves it for gout, for high uric acid caused by cancer treatment, and for recurrent calcium oxalate kidney stones in adults with high uric acid in the urine. The label says it is not recommended for high uric acid without symptoms. This page is about the tablets.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have gout, cancer-treatment-related high uric acid, or recurrent calcium oxalate stones with high urine uric acid, and your prescriber recommends allopurinol
You can have the baseline and follow-up blood tests the label lists
You understand the label's instruction to stop it and contact your doctor right away if a rash appears

Probably skip if…

You have had a hypersensitivity reaction to allopurinol (contraindicated)
You only have high uric acid without symptoms, where the label says it is not recommended
You carry HLA-B*58:01, where the label says it is not recommended unless benefits clearly outweigh risks
You hope it will prevent heart attacks or slow kidney disease without gout; trials found it did not

Evidence at a glance

lowering blood uric acid in gout

Good Evidence
Effect
Large on uric acid; fewer attacks not shown in short trials
Best fit
Adults with chronic gout
Time
Uric acid target measured at 30 days

preventing heart attacks and strokes in heart disease without gout (not an approved use)

Good Evidence
Effect
None
Best fit
Not applicable; no benefit was found
Time
Mean follow-up 4.8 years

slowing chronic kidney disease without gout (not an approved use)

Good Evidence
Effect
None
Best fit
Not applicable; no benefit was found
Time
Measured over 2 years

Evidence for 3 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

lowering blood uric acid in gout

Biomarker support
Good Evidence

A Cochrane review of 11 trials (4,531 people with chronic gout) treated allopurinol versus placebo as its main comparison. In one trial of 57 participants (moderate-quality evidence), 25 of 26 people on allopurinol 300 mg a day reached the target uric acid level over 30 days versus 0 of 25 on placebo. The same trial did not show fewer gout attacks over that short period (2 of 26 vs 3 of 25). Against febuxostat 80 mg a day, fewer people reached target uric acid on allopurinol 300 mg (38% vs 70%), with no clear difference in gout attacks.

Effect size
Large on uric acid; fewer attacks not shown in short trials
Time to effect
Uric acid target measured at 30 days
Best fit
Adults with chronic gout
Less likely
People with high uric acid but no gout, stones or cancer treatment, for whom it is not recommended

Bottom line: Allopurinol brought more people to target uric acid than placebo; at 300 mg a day fewer reached target than with febuxostat 80 mg, and short trials were too small to show fewer gout attacks.

preventing heart attacks and strokes in heart disease without gout (not an approved use)

No benefit found
Good Evidence

This is not an approved use. In the open-label ALL-HEART trial, 5,721 people aged 60 or older with ischemic heart disease and no history of gout were randomized to allopurinol (up to 600 mg a day) or usual care and followed for a mean of 4.8 years. Heart attack, stroke or cardiovascular death occurred in 11.0% on allopurinol and 11.3% on usual care (hazard ratio 1.04), and deaths from any cause did not differ (10.1% vs 10.6%). Almost all participants (99.2%) were white.

Effect size
None
Time to effect
Mean follow-up 4.8 years
Best fit
Not applicable; no benefit was found
Less likely
Older adults with ischemic heart disease and no gout

Bottom line: Allopurinol did not lower heart attacks, strokes or deaths in older people with heart disease who did not have gout.

slowing chronic kidney disease without gout (not an approved use)

No benefit found
Good Evidence

This is not an approved use. In the CKD-FIX trial, 363 adults with stage 3 or 4 chronic kidney disease at high risk of progression and no history of gout took allopurinol 100 to 300 mg a day or placebo for 104 weeks. Kidney function (eGFR) fell by 3.33 mL/min/1.73 m2 per year on allopurinol and 3.23 on placebo, no significant difference. The trial stopped early for slow recruitment after enrolling 369 of 620 planned patients.

Effect size
None
Time to effect
Measured over 2 years
Best fit
Not applicable; no benefit was found
Less likely
Adults with stage 3 or 4 chronic kidney disease and no gout

Bottom line: Allopurinol did not slow kidney function decline in people with chronic kidney disease who did not have gout.

How it works

Allopurinol and its active product oxypurinol block xanthine oxidase, the enzyme that makes uric acid. Lower uric acid in the blood lets urate crystals in joints slowly dissolve, which over months makes gout attacks shorter and less frequent. Early in treatment, shifting urate can trigger flares, so the label recommends a flare-preventing medicine such as colchicine when allopurinol is started. Allopurinol itself has a half-life of 1 to 2 hours, but oxypurinol lasts about 15 hours, which is why once-daily dosing works. Because xanthine oxidase also breaks down azathioprine and mercaptopurine, allopurinol makes those drugs much stronger, a critical interaction. The label also says allopurinol's drowsiness can add to the effects of alcohol and other sedating substances, and it advises drinking enough fluid to pass at least 2 liters of urine a day.

How to take it

1. Typical dose
Your prescriber sets the dose. The label lists: gout, 100 mg once daily to start (50 mg in kidney impairment), raised by 100 mg each week until blood uric acid is 6 mg/dL or less; the minimal effective dose is 100 to 200 mg a day, mild gout usually needs 200 to 300 mg and moderate to severe tophaceous gout 400 to 600 mg; uric acid from cancer treatment, 300 to 800 mg a day in adults, started 24 to 48 hours before chemotherapy. Lower doses are used in kidney disease.
2. Higher studied dose
The maximum recommended dose is 800 mg a day. Doses above 300 mg are split into more than one dose.
3. Timing
Usually once a day. If a dose is missed, the label says there is no need to double the next dose.
4. With food
The label says it is generally better tolerated taken after meals. Drink enough fluid to pass at least 2 liters of urine a day.
5. Split dosing
Doses over 300 mg a day are divided.
6. How long to try
Usually long term for gout, as your prescriber decides. The label says to keep taking it even if flares happen early on, together with any flare-prevention medicine your prescriber gives, and to stop it and get medical advice at the first sign of a rash. Do not change the dose on your own.

What to track

Any rash, blisters, peeling skin, mouth sores, fever or swollen glands, especially in the first months (the label says to stop it and seek medical care promptly)
Blood uric acid level, aiming at the target your prescriber sets (often 6 mg/dL or less)
Kidney function, liver tests and blood counts, as your prescriber schedules them
Gout flares in the first months, which do not mean the drug is failing
Drowsiness or dizziness when starting or raising the dose, especially with alcohol
Any new prescription for azathioprine, mercaptopurine, capecitabine, fluorouracil, warfarin or cyclosporine (the label says to avoid allopurinol during capecitabine treatment and to avoid giving it with fluorouracil)

Bottom line: Your prescriber sets and adjusts the dose to your uric acid level; the label says to take it after a meal with plenty of fluid, and to stop it and seek care at the first rash.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Skin rash, the most frequent side effectDiarrhea and nauseaRaised liver enzymes on blood testsGout flares in the first months of treatmentDrowsiness or dizziness in some people

Serious risks

  • Serious and sometimes fatal skin and hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, in about 5 in 10,000 people (0.05%), mostly in the first few months. The risk is higher with the HLA-B*58:01 gene, more common in people of African, Asian (for example Han Chinese, Korean, Thai) and Native Hawaiian or Pacific Islander ancestry. The label says to stop allopurinol permanently at the first sign of a rash. The current label has no boxed warning.

  • Kidney injury from xanthine stones or urate deposits, with higher risk in existing kidney disease or a history of stones; the label advises enough fluid for at least 2 liters of urine a day.

  • Liver injury (usually reversible) and low blood counts (anemia, low white cells or platelets), which have occurred from 6 weeks to 6 years after starting.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the allopurinol label says that, based on animal findings, it may cause fetal harm, and that allopurinol and oxypurinol cross the placenta. Limited published human data (about 50 pregnancies) do not show a clear pattern of birth defects, although 2 infants with major malformations were reported. Anyone pregnant or planning pregnancy should discuss this with their doctor. Breastfeeding: the label says allopurinol and oxypurinol are present in human milk and, because of the potential for serious adverse reactions in a breastfed child, advises women not to breastfeed during treatment and for one week after the last dose.

Interactions

Azathioprine (and mercaptopurine)Critical

Allopurinol blocks xanthine oxidase, which breaks down azathioprine and mercaptopurine, so their levels and toxicity rise and can cause dangerous bone marrow suppression. The allopurinol label says that with 300 to 600 mg of allopurinol a day, the azathioprine or mercaptopurine dose needs to be cut to about one-third to one-quarter of usual. They should be combined only when the prescriber managing the azathioprine has planned it, with close blood count checks.

PegloticaseHigh

The label says allopurinol may blunt the rise in uric acid levels during pegloticase treatment and increase the risk of pegloticase-related anaphylaxis in people whose uric acid rises above 6 mg/dL, and that allopurinol should be stopped and not started during pegloticase treatment. Your rheumatologist manages this.

Ampicillin, amoxicillin, thiazide diuretics and bendamustineModerate

The label says these may raise the risk of skin rash with allopurinol, which may be severe, and that the thiazide risk is higher with reduced kidney function. Tell your prescriber you take allopurinol before an antibiotic or water pill is started, and report any rash right away.

WarfarinModerate

The label says allopurinol may slow the breakdown of warfarin and strengthen its blood-thinning effect, and recommends checking the INR often when allopurinol is added. Make sure the clinic managing your warfarin knows.

AlcoholLow

The label says drowsiness, somnolence and dizziness have been reported with allopurinol and that its central nervous system depressant effects may be additive to those of alcohol. It advises against driving or using machinery when starting allopurinol or raising the dose, until you know how it affects you. No study has tested the combination.

Documented interactions

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Generic allopurinol (100 mg or 300 mg scored tablets) or Zyloprim on your own prescription
Instructions to take it after meals with plenty of fluid
The warning to stop it and seek care at the first sign of a skin rash
A pharmacy record note that flags azathioprine or mercaptopurine prescriptions

Be skeptical of…

"Natural uric acid support" or "gout cleanse" supplements presented as a replacement for prescribed treatment
Claims that allopurinol protects the heart or kidneys in people without gout; randomized trials found it did not
Advice to stop allopurinol during a gout flare; the label says to keep taking it
Online sellers offering allopurinol without a prescription

Frequently asked questions

Can I take azathioprine with allopurinol?⌄

Only if the prescriber managing your azathioprine has planned it. This page rates the pair critical: allopurinol blocks the enzyme that breaks down azathioprine, and the label says the azathioprine dose must be cut to about one-third to one-quarter of usual, with close blood count monitoring. The same applies to mercaptopurine.

Can I drink alcohol while taking allopurinol?⌄

The allopurinol label says it can cause drowsiness or dizziness, that its effects on the nervous system may add to those of alcohol and other sedating substances, and that you should not drive or use dangerous machinery when starting or raising the dose until you know how it affects you. Ask your doctor or pharmacist how much, if any, is reasonable for you.

Why did my gout flares get worse when I started allopurinol?⌄

The label explains that falling uric acid moves urate out of tissue deposits, which can trigger flares early on, and that control can take several months. It recommends a flare-preventing medicine at the start and says to keep taking allopurinol during a flare. Talk to your prescriber about flare prevention.

Should I take allopurinol with food?⌄

The label says it is generally better tolerated after meals, and to drink enough fluid to pass at least 2 liters of urine a day to help prevent kidney stones.

What should I do if I get a rash on allopurinol?⌄

The label says to stop allopurinol right away and seek medical attention promptly at the first sign of a rash, because rare reactions such as Stevens-Johnson syndrome can be serious or fatal. Contact your doctor or pharmacist the same day.

References by claim

lowering blood uric acid in gout

Seth et al., 2014 · PMC (2014) link

preventing heart attacks and strokes in heart disease without gout (not an approved use)

Mackenzie et al., 2022 · PubMed (2022) link

slowing chronic kidney disease without gout (not an approved use)

Badve et al., 2020 · PubMed (2020) link

Safety

Allopurinol tablets prescribing information · DailyMed (FDA label) link

Interaction: Azathioprine (and mercaptopurine)

Imuran (azathioprine) prescribing information · DailyMed (FDA label) link

Track Allopurinol with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 20, 2026·Evidence current as of Nov 20, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.